TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA · XNYSCIK 818686fmd_03PSJXMXXNVJX0R7PADE005SZ3Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2007 to Sep 30, 2026, 76 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 21,903 | 21,853 | 18,271 | 16,887 | 16,659 | 15,878 | 14,925 | 15,846 | 16,544 | 17,258 |
| Cost of revenue | 10,250 | 11,237 | 9,975 | 9,351 | 8,933 | 8,284 | 7,952 | 8,200 | 8,481 | 8,320 |
| Gross profit | 11,653 | 10,615 | 8,296 | 7,537 | 7,726 | 7,594 | 6,973 | 7,645 | 8,064 | 8,938 |
| Research and development | 422 | 175 | 114 | 1,010 | 997 | 967 | 98 | 953 | 998 | 1,013 |
| Selling, general and administrative | 4,973 | 4,846 | 4,214 | 3,806 | 3,671 | 3,528 | 3,445 | 3,498 | 3,702 | 3,973 |
| Operating income | 2,154 | (17,484) | (1,637) | (443) | (3,572) | 1,716 | (2,197) | 433 | (303) | 2,157 |
| Interest expense | 546 | 875 | 920 | 822 | 901 | 891 | 930 | 1,029 | 1,002 | 916 |
| Other non-operating income (expense) | (1,330) | (895) | (959) | (822) | (834) | (1,058) | (966) | (1,057) | (981) | (934) |
| Income before taxes | 824 | (18,379) | (2,596) | (1,265) | (4,406) | 658 | (3,163) | (624) | (1,284) | 1,223 |
| Income tax expense | 521 | (1,933) | (195) | (278) | (168) | 211 | (643) | (7) | 676 | (180) |
| Net income from continuing operations | 303 | (16,446) | (2,401) | (987) | (4,238) | 447 | (2,520) | (617) | (1,960) | 1,403 |
| Net income | 329 | (16,265) | (2,150) | (999) | (3,990) | 417 | (2,446) | (559) | (1,639) | 1,410 |
| Net income to common shareholders | 68 | (16,525) | (2,399) | (999) | (3,990) | 417 | (2,446) | (559) | (1,639) | 1,410 |